TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01318083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
Study: NCT01902797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
Study: NCT03844633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera Injectable Product
Description: Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos -- Shot administered within 48 hours of childbirth
Study: NCT03765346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone IR ADF
Description: Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone API powder
Description: Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
Study: NCT02829983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-stage full-mouth ultrasonic debridement (FMUD)
Description: One session of Periodontal debridement using ultrasonic device.
Study: NCT03765346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match oxycodone API powder
Description: Placebo to match oxycodone API powder (mass of 30 mg).
Study: NCT02829983

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: One-stage full-mouth ultrasonic debridement (FMUD)
Description: One session of Periodontal debridement using ultrasonic device.
Study: NCT01765660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
Study: NCT03765346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match oxycodone API powder
Description: Placebo to match oxycodone API powder (mass of 30 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match manipulated oxycodone IR ADF.
Description: Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
Study: NCT01962298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single rocuronium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single rocuronium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repeated rocuronium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repeated rocuronium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous rocuronium infusion
Study: NCT00246662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: All patients receive vosaroxin Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: All patients receive vosaroxin Injection
Study: NCT02340962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
Study: NCT01963832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02340962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
Study: NCT00070122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT01963832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eCMIT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual Care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual Care
Study: NCT02172261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study: NCT04626921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: 30 mg of CNM-Au8
Study: NCT03190083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-dimensional mammogram
Description: This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
Study: NCT02172261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Study: NCT01517178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New ostomy base plate (SS)
Description: The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care base plate
Description: The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
Study: NCT04551586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Immediate Release
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Immediate Release
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Immediate Release
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Powder-in-capsule
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Powder-in-capsule
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Powder-in-capsule
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Study: NCT02013908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard ED management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ED management alone
Study: NCT04162158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic NK cells therapy
Description: PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
Study: NCT03190083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital breast tomosynthesis (DBT)
Description: The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
Study: NCT00688961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: generic aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: generic aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: 4, 1 g capsules q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: 4, 1 g capsules q.d.
Study: NCT03869242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-200A
Description: newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
Study: NCT03155191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1501
Description: Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501.
Study: NCT05752578

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).

Intervention type: OTHER
Intervention: Neuropsychological testing
Description: During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
Study: NCT01765660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-mesenchymal stem cells
Description: Other second line drugs are taken.
Study: NCT03312400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
Study: NCT03280043

Intervention type: PROCEDURE
Intervention: Hematoma
Description: Hematoma requiring return to operating room.
Study: NCT03370289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLB-750 Vaccine (Qinghai RG strain)
Description: BLB-750 Injection
Study: NCT05570201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
Study: NCT04214184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased sleep duration
Description: Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
Study: NCT02734420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PapacarieMBlue and PDT
Description: Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toluidine Blue O and PDT
Description: Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study: NCT00590460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Given intravenous on days -8, -7, and -6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Stem cells are infused on day 0
Study: NCT03765346

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match manipulated oxycodone IR ADF.
Description: Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
Study: NCT01657682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Description: Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Description: Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
Study: NCT04837950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic traction-suture
Description: Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic traction-suture
Description: Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture
Study: NCT00847093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX4
Description: One inch every six hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX4 Placebo
Description: One inch every six hours
Study: NCT03487874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional interscalene block
Description: Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene block with C8 root block
Description: Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Study: NCT02829424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate Placebo
Description: Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
Study: NCT04239287

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function + exercise tests
Description: Lung function + exercise tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function + exercise tests
Description: Lung function + exercise tests
Study: NCT04887961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD and Trabectedin rechallenge
Description: Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
Study: NCT01373047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA 2nd generation designer T cells
Description: Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
Study: NCT02284464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal
Description: Withdrawal of steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone continuation
Description: Continuation of steroids
Study: NCT01894958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution
Study: NCT03291600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Psychiatric Care
Description: Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
Study: NCT01882894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom PFO
Description: PFO made out of thermoplastic material molded to the patient's foot

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faux orthosis
Description: Foam cut out
Study: NCT03906487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM
Description: This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~* the last to characterize the SDM by defining 5 personal memories

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment measures MINI and definition of 5 SDM
Description: This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~* the last to characterize the SDM by and defining 5 personal memories